Page 445«..1020..443444445446

Bucking US decline, region’s start-ups lure more money – Boston Globe

By Dr. Matthew Watson


VentureBeat
Bucking US decline, region's start-ups lure more money
Boston Globe
Still, 2010 is off to a better start than 2009, as biotechnology and medical devices continued to lead other industries in both number of deals and money ...
Venture funding rebounds for Austin startupsAustin American-Statesman
Summary Box: Venture-Cap Investments Rise In 1QCBS 5
Venture-cap investments rise in 1Q, as optimism upThe Associated Press
Bizjournals.com -techrockies.com
all 127 news articles »

To Read More: Bucking US decline, region’s start-ups lure more money – Boston Globe
categoriaUncategorized commentoComments Off on Bucking US decline, region’s start-ups lure more money – Boston Globe | dataApril 16th, 2010
Read All

Weak Kidneys Cause Weak Bones

By Dr. Matthew Watson

by Jean-Claude Alix, Naturopath

No single area of the body stands alone, everything is linked up. This is why medical specialisation is one of the greatest mistakes that was ever

made.

Viewed from this angle, hardly any two areas are so closely and deeply intertwined as the renal metabolism and the bone metabolism. Thus, it is understandable that weakness in the kidneys must necessarily result in weakness in the bones. The discussion of these interrelations is the

theme of this treatise.

Significance of the kidney as the centre of bone formation:

- The kidney as regulator of the

electrolytes

- The kidney as regulator of the

acid-alkaline balance

- The kidney as the base of anxiety Read more...

Joint Mender for Joint Care

To Read More: Weak Kidneys Cause Weak Bones
categoriaIntegrative Medicine commentoComments Off on Weak Kidneys Cause Weak Bones | dataApril 15th, 2010
Read All

3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues – Wired News

By Dr. Matthew Watson


Reuters
3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues
Wired News
The technique is a subtle form of genetic engineering, which many people consider taboo, and raises other ethical dilemmas. It could also allow parents ...
Three-Parent Babies Due Soon, Thanks to ScienceFOXNews

all 145 news articles »

To Read More: 3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues – Wired News
categoriaUncategorized commentoComments Off on 3-Parent Embryos Could Prevent Disease, But Raise Ethical Issues – Wired News | dataApril 15th, 2010
Read All

CORRECTED: Are regulators dropping the ball on biocrops? – Reuters

By Dr. Matthew Watson


Reuters
CORRECTED: Are regulators dropping the ball on biocrops?
Reuters
"One of the things that we think is important to do is to have regular reviews and updates of our strategies for regulating products of biotechnology," said ...
Are US regulators dropping the ball when it comes to biocrops?BusinessWorld Online
SPECIAL REPORT-Are US regulators dropping the ball on biocrops?Forexyard

all 18 news articles »

To Read More: CORRECTED: Are regulators dropping the ball on biocrops? – Reuters
categoriaUncategorized commentoComments Off on CORRECTED: Are regulators dropping the ball on biocrops? – Reuters | dataApril 15th, 2010
Read All

F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent

By Dr. Matthew Watson

Plans by  FDA to Adopt stricter standards for Bioequivalence, Bioavailability for generic drugs could sound trouble for Indian Generic Manufactures. Already most of the smaller companies are finding it difficult to get FDA approval letters. QSR Draft Guidance An industry working group has urged the FDA to consider adopting its guidance to outline quality system requirements (QSR) for bioequivalence and bioavailability testing during drug clinical trials.

There was a recent report in NY times that mentioned about several thousand patients receiving nitroglycerin tablets that were not approved by FDA http://www.nytimes.com/2010/03/27/business/27nitro.html

FDA recently evaluated 2070 human studies conducted between 1996 and 2007. These studies compared the absorption of brand name and generic drugs into a person’s body. These studies were submitted to FDA to support approval of generics. The average difference in absorption into the body between the generic and the brand name was only 2.3%. Some generics were absorbed slightly more, some slightly less. This amount of difference would be expected and acceptable, whether for one batch of brand name drug tested against another batch of the same brand, or for a generic tested against a brand name. In fact, there have been studies in which branded drugs were compared with themselves, as well as with a generic. As a rule, the difference for the generic-to-brand comparison was about the same as the brandto- brand comparison” (www.fda.gov/ Drugs/ResourcesForYou/Consumers/ BuyingUsingMedicineSafely/Under standingGenericDrugs/ucm167991. htm)

Fore more updates attend the event below

Attend the http://www.informaglobalevents.com/event/beba

To Read More: F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent
categoriaUncategorized commentoComments Off on F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent | dataApril 15th, 2010
Read All

East Africa: South Africa Leads in GM Crops as EA Lags Behind – AllAfrica.com

By Dr. Matthew Watson


Reuters
East Africa: South Africa Leads in GM Crops as EA Lags Behind
AllAfrica.com
With reduced requirements for farm inputs and increased yields per unit area, genetic engineering, a modern form of biotechnology, could transform the ...
Green thumbsTruth about Trade & Technology
Weeds improve resistance to RoundupSt. Louis Post-Dispatch
Some weeds, bugs grew resistant to genetically engineered cropsUSA Today
Environment News Service -Treehugger -DesMoinesRegister.com
all 59 news articles »

To Read More: East Africa: South Africa Leads in GM Crops as EA Lags Behind – AllAfrica.com
categoriaUncategorized commentoComments Off on East Africa: South Africa Leads in GM Crops as EA Lags Behind – AllAfrica.com | dataApril 14th, 2010
Read All

US Reps propose tougher Medicare fraud penalties – WZVN-TV

By Dr. Matthew Watson


Journal Record (subscription)
US Reps propose tougher Medicare fraud penalties
WZVN-TV
The proposed bill would double prison sentences for Medicare fraud and use biotechnology such as fingerprint scanning to ensure patients are getting the ...
House bill would double Medicare fraud penaltiesJournal Record (subscription)

all 23 news articles »

To Read More: US Reps propose tougher Medicare fraud penalties – WZVN-TV
categoriaUncategorized commentoComments Off on US Reps propose tougher Medicare fraud penalties – WZVN-TV | dataApril 14th, 2010
Read All

International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCO), http://www.intlstemcell.com, today added two world-leading immunogeneticists to its scientific advisory board. They and ISCO scientists will study the immune-matching properties of ISCO's human parthenogenetic stem cell (hpSC) technology and the potential for each hpSC-derived therapeutic cell to be an immune-match for millions of people.

Dr. Hans-Dieter Volk, Professor of Immunology and Chair of the Institute of Medical Immunology and Berlin-Brandenburg Center for Regenerative Therapies (BCRT) at Charité Universitätsmedizin in Berlin, and Dr. Matthias von Herrath, Professor at the La Jolla Institute of Allergy and Immunology at University of San Diego, have agreed to join ISCO's scientific advisory board. Both have dedicated their careers to experimental and clinical immunology and are highly regarded immunogenetics experts internationally. They will be most valuable as ISCO attempts to demonstrate the unique immune-matching benefits of the hpSC technology experimentally and in clinical practice.

"We believe that providing human cells that can minimize rejection though immune-matching to the recipient is one of the most important tasks in developing effective regenerative medicine therapies," says Dr. Simon Craw, Vice President at ISCO. "We look forward to Drs. Volk and von Herrath helping us try to demonstrate how that need can be met with our parthenogenetic stem cells."

Embryonic stem cells (hESC) almost invariably have different forms of genes (called "alleles") at each genetic position of the paternal and maternal chromosomes, i.e. they are "heterozygous." This includes the human leukocyte antigen ("HLA") genes that are largely responsible for the distinction between "self" and "foreign," and thus acceptance or rejection of transplants. Since hESC are derived from fertilized embryos, they carry the genes of a unique individual, thus the therapeutic cells derived from hESC will carry HLA alleles that can be recognized as foreign and be rejected by most patients unless they receive immunosuppressive therapy. Such therapy is costly, has significant side effects, and often is disabling in the long term.

Like most individuals in the population, induced pluripotent stem cells ("iPS" cells) and adult stem cells are also predominantly heterozygous because they carry paternal and maternal chromosomes. They are a perfect immune match to the patient they came from and are therefore typically administered back to that same individual ("autologous therapy"). However, they would likely be rejected by most other recipients. Autologous therapy is time-consuming and expensive, which goes against the cost containment pressures globally. In addition, the quality of the therapy is directly related to the ability to secure clinically sufficient numbers of functional cells from the patient, which often poses a significant problem in clinical practice.

In contrast, the hpSCs developed by ISCO are derived from unfertilized eggs ("oocytes") that have been shown in peer-reviewed journals to exhibit unlimited proliferation potential and are pluripotent (can become cells from all three germ layers that form a human being). Most significantly, hpSC can be created in a "homozygous" state, where the alleles, including the HLA alleles, are the same at each genetic position. When these HLA alleles are also found with a high frequency in a population, these "HLA-homozygous" stem cells and their therapeutic derivatives have the potential to be immune matched to millions of people. For example, ISCO's first homozygous stem cell line with high-frequency HLA alleles has the potential to be immune matched to an estimated 75 million people worldwide.

Dr. Volk says: "Using my experience from transplantation immunology and medicine during the past three decades, I am very pleased to help ISCO in their efforts to make its hpSC technology a clinical reality where therapeutic cell derivatives will be immune matches for millions of people worldwide." Dr. von Herrath continues: "While stem cell technologies generally offer great regenerative potential, most clinical applications will be limited by immune rejection. I look much forward to joining ISCO in their quest for making stem cell-derived therapy a practical and attractive clinical option for many degenerative diseases."

Besides the immunogenetic developments, ISCO is advancing its hpSC technology into the differentiation of hpSC into therapeutic cells and tissues and into the establishment of processes and facilities to produce clinical-grade cells. The company is seeking to demonstrate the therapeutic potential of its hpSC technology as a safe, efficient, and superior alternative to other sources of stem cells for human therapy.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

To Read More: International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells | dataApril 14th, 2010
Read All

Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue – Legal Info Today

By Dr. Matthew Watson


TopNews United States
Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue
Legal Info Today
A successful ACLU lawsuit against the biotechnology company Myriad Genetics over the BRCA gene has some celebrating and others alarmed. ...
The profit strandThe Age
Making sense of patentsABC Online
Is it fair to patent genes? ACLU takes on biotech over issueUSA Today
Bizmology -Los Angeles Times -American Medical News
all 20 news articles »

To Read More: Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue – Legal Info Today
categoriaUncategorized commentoComments Off on Law Headlines:Is it fair to patent genes? ACLU takes on biotech over issue – Legal Info Today | dataApril 14th, 2010
Read All

Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research … – Pharmaceutical Business Review

By Dr. Matthew Watson


Live-PR.com (press release)
Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research ...
Pharmaceutical Business Review
According to a research conducted by a group of scientists in partnership with professor Michael Krainer, director of the molecular genetics working group, ...
New options for the treatment of ovarian cancerPharmacy Europe

all 62 news articles »

To Read More: Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research … – Pharmaceutical Business Review
categoriaUncategorized commentoComments Off on Monoclonal Antibodies Promise New Chances For Ovarian Cancer Therapy: Research … – Pharmaceutical Business Review | dataApril 14th, 2010
Read All

CSC news roundup 2010-04-11

By Dr. Matthew Watson

To Read More: CSC news roundup 2010-04-11
categoriaStem Cell Therapy commentoComments Off on CSC news roundup 2010-04-11 | dataApril 12th, 2010
Read All

Sunlight May Help Protect Men From Kidney Cancer

By Dr. Matthew Watson

(HealthDay News) -- Men with jobs that expose them to high levels of sunlight are less likely to develop kidney cancer than those with little or no sunlight exposure at work, says a new study.

Previous research suggests that vitamin D, which is obtained from sun exposure and certain foods and supplements, may help prevent some cancers. Vitamin D is metabolized and most active within the kidneys.

This new study included 1,097 male and female kidney cancer patients and 1,476 healthy people in Europe who were interviewed about their work history and other demographic information.

Men with the highest levels of work-related exposure to sunlight were 24 percent to 38 percent less likely to have kidney cancer than other men. This association between job-related sunlight exposure and kidney cancer risk was not seen in women.

The study is published online March 8 in the journal Cancer. Read more...

Ayurtox for Body Detoxification

To Read More: Sunlight May Help Protect Men From Kidney Cancer
categoriaIntegrative Medicine commentoComments Off on Sunlight May Help Protect Men From Kidney Cancer | dataApril 10th, 2010
Read All

ProShares Launches Two New Exchange Traded Funds Based on the NASDAQ … – CNNMoney.com (press release)

By Dr. Matthew Watson


ETF Database
ProShares Launches Two New Exchange Traded Funds Based on the NASDAQ ...
CNNMoney.com (press release)
2 ProShares Ultra Nasdaq Biotechnology (Nasdaq:BIB) aims to provide investment results that correspond to 200% of the daily performance of the NASDAQ ...
ProShares Launches First Leveraged and Inverse Biotechnology ETFsMarketWatch (press release)
Avoid New Biotech Leveraged ETFsTheStreet.com (subscription)
Double Your Biotech Returns! Really!Motley Fool
Benzinga -Before It's News -Emii.com
all 52 news articles »

To Read More: ProShares Launches Two New Exchange Traded Funds Based on the NASDAQ … – CNNMoney.com (press release)
categoriaUncategorized commentoComments Off on ProShares Launches Two New Exchange Traded Funds Based on the NASDAQ … – CNNMoney.com (press release) | dataApril 10th, 2010
Read All

Generex Biotechnology Firms About 4% on Funding Commitment – ONN.tv

By Dr. Matthew Watson


BNET
Generex Biotechnology Firms About 4% on Funding Commitment
ONN.tv
by MidnightTrader.com April 8, 2010 11:07 EDT Related Symbols: GNBT 11:07 AM Eastern Daylight Time, 04/08/2010 (MidnightTrader) — Generex Biotechnology ...
Generex Receives Funding CommitmentMarketWatch (press release)
Generex Receives Funding CommitmentTrading Markets (press release)

all 23 news articles »

To Read More: Generex Biotechnology Firms About 4% on Funding Commitment – ONN.tv
categoriaUncategorized commentoComments Off on Generex Biotechnology Firms About 4% on Funding Commitment – ONN.tv | dataApril 10th, 2010
Read All

Trading looks for biotechs to decline – optionMONSTER Research (registration)

By Dr. Matthew Watson


ETF Trends (blog)
Trading looks for biotechs to decline
optionMONSTER Research (registration)
Unusual option action is showing that someone is positioning for a pullback in the Nasdaq Biotechnology Index Fund. The IBB exchange-traded fund is off 0.17 ...
ETFs and EarningsTheStreet.com (subscription)
Nine ETFs To Buy NowForbes
This Week in ETFs: April 9th EditionETF Database

all 52 news articles »

To Read More: Trading looks for biotechs to decline – optionMONSTER Research (registration)
categoriaUncategorized commentoComments Off on Trading looks for biotechs to decline – optionMONSTER Research (registration) | dataApril 10th, 2010
Read All

US Sen. Bob Casey presents Hanover Township biotechnology company ABEC with award – The Express Times – LehighValleyLive.com

By Dr. Matthew Watson


The Express Times - LehighValleyLive.com
US Sen. Bob Casey presents Hanover Township biotechnology company ABEC with award
The Express Times - LehighValleyLive.com
Local biotechnology company ABEC received a prestigious national award Friday for its success breaking into the international marketplace. US Sen. ...
Bob Casey presents award to Lehigh Valley businessThe Express Times - LehighValleyLive.com
Sen. Bob Casey to visit ABEC Inc. company in Hanover TownshipThe Express Times - LehighValleyLive.com

all 3 news articles »

To Read More: US Sen. Bob Casey presents Hanover Township biotechnology company ABEC with award – The Express Times – LehighValleyLive.com
categoriaUncategorized commentoComments Off on US Sen. Bob Casey presents Hanover Township biotechnology company ABEC with award – The Express Times – LehighValleyLive.com | dataApril 10th, 2010
Read All

HIV invades through leaky cells: study – CBC.ca

By Dr. Matthew Watson


India Talkies
HIV invades through leaky cells: study
CBC.ca
The research was conducted in collaboration with researchers in the department of molecular genetics at the University of Toronto and the department of ...
New way HIV infects women discoveredOneindia

all 61 news articles »

To Read More: HIV invades through leaky cells: study – CBC.ca
categoriaUncategorized commentoComments Off on HIV invades through leaky cells: study – CBC.ca | dataApril 9th, 2010
Read All

International Stem Cell Corporation Provides Strategic Update on its Skin Care Program

By Dr. Matthew Watson

OCEANSIDE, California - April 8, 2010 - International Stem Cell Corporation (ISCO.OB), http://www.internationalstemcell.com, announces today that it’s wholly owned subsidiary, Lifeline Skin Care Inc., has achieved positive results in human safety tests of its cosmetic products and is moving forward with arrangements with Cosmetic Enterprises Ltd. for the manufacture of three cosmetic products. These developments allow Lifeline Skin Care to plan a launch of its cosmetic product line in the late summer or fall of 2010.

Cosmetic face products developed by Lifeline Skin Care Inc., contain extracts from human parthenogenetic stem cells (hpSC) combined with a vitamin complex and other active ingredients. The products utilize a form of nanotechnology to deliver concentrated active ingredients to damaged skin. Laboratory tests show that an active “complex” of stem cell extract has the ability to rejuvenate skin. Also, early human trials show that these cosmetic products moisturize skin and strongly indicate the ability to decrease the depth of wrinkles and provide factors that lead to anti-aging effects.

Lifeline Skin Care is working with Cosmetic Enterprises, Ltd., located in California, to formulate and package its unique skin care product. Cosmetic Enterprises is a well-known OTC drug licensed manufacturer with over 30 years of experience. Lifeline Skin Care’s “parthenogenetic stem cell complex” the product’s active ingredient, is made in Lifeline Skin Care’s laboratory in Oceanside, California.


According to Gregory S. Keller, MD, FACS, “These positive safety studies in human testing are important, especially considering that preliminary human trial data show that products of the production of International Stem Cell’s parthenogenetic stem cells have significant beneficial effects on the skin and might also provide long term benefits in reducing wrinkles and other visible signs of aging. These results are a significant step forward in making this unique product available to the public.” Dr. Keller was named the 2007 “Specialist of the Year in Facial Cosmetic Surgery” in Strathmore’s “Who’s Who”.


The results of recent human safety tests show there were no identifiable signs or symptoms of sensitization (contact allergy). Safety testing is a series of tests to insure the product does not cause negative reactions such as irritation to the skin. This completed round of testing allows Lifeline Skin Care to move forward confidently with its commercial manufacturing plans.
International Stem Cell Corporation is a pioneer in development of a new class of stem cells called “human parthenogenetic stem cells” which avoid critical ethical issues by eliminating the need to use fertilized embryos and can be immune-matched to large segments of the population. As of today, ISCO has successfully derived 10 hpSC lines. One of these lines (hpSC-Hhom-4), carries the most common immune type found across racial groups within the US population and can be immune-matched to millions of people.


ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO’s core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO’s website,
http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.


Key Words: Skin Care, Stem Cells, Biotechnology, Parthenogenesis


CONTACTS:
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
Or
Lifeline Skin Care Inc.
Ruslan Semechkin, PhD, CEO
760-940-6383
ras@intlstemcell.com

To Read More: International Stem Cell Corporation Provides Strategic Update on its Skin Care Program
categoriaStem Cell Therapy commentoComments Off on International Stem Cell Corporation Provides Strategic Update on its Skin Care Program | dataApril 9th, 2010
Read All

Generex Launches $250000000 Lawsuit Against TheStreet.com and Feuerstein – MarketWatch (press release)

By Dr. Matthew Watson


TheStreet.com
Generex Launches $250000000 Lawsuit Against TheStreet.com and Feuerstein
MarketWatch (press release)
WORCESTER, Mass., Apr 6, 2010 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (NASDAQ:GNBT) (www.generex.com), the leader in drug delivery ...
Generex: What Happens in India, Stays in IndiaTheStreet.com
TheStreet stands up to Generex's bullyingEthiopian Review
Generex Launches $250000000 Lawsuit Against TheStreet.com and FeuersteinTrading Markets (press release)

all 12 news articles »

To Read More: Generex Launches $250000000 Lawsuit Against TheStreet.com and Feuerstein – MarketWatch (press release)
categoriaUncategorized commentoComments Off on Generex Launches $250000000 Lawsuit Against TheStreet.com and Feuerstein – MarketWatch (press release) | dataApril 7th, 2010
Read All

Faulty Circuits (preview)

By Dr. Matthew Watson

In most areas of medicine, doctors have historically tried to glean something about the underlying cause of a patient’s illness before figuring out a treatment that addresses the source of the problem. When it came to mental or behavioral disorders in the past, however, no physical cause was detectable so the problem was long assumed by doctors to be solely “mental,” and psychological therapies followed suit.

Today scientific approaches based on modern biology, neuroscience and genomics are replacing nearly a century of purely psychological theories, yielding new approaches to the treatment of mental illnesses.

[More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


To Read More: Faulty Circuits (preview)
categoriaUncategorized commentoComments Off on Faulty Circuits (preview) | dataApril 7th, 2010
Read All

Page 445«..1020..443444445446